N/A N=42 Compatibility of a Mild, Moisturizing Hand Cleanser for Patients With Mild to Moderate Hand Dermatitis
Hand Dermatosis
Primary: Investigator Global Assessment — 1.0; 1.1 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=20 A Study for a Topical Medication Versus Placebo in Patients With Hand Dermatitis
Hand Dermatitis
Primary: Primary Outcome Measure for Efficacy (IGA) — 2.33; 2.20; 2.43; 2 score on a scale
Phase 2 N=16 Topical Ruxolitinib in Chronic Hand Dermatitis
Chronic Hand Dermatitis
Primary: Proportion of Patients With Chronic Hand Dermatitis Improvement as Assessed by Investigators Global Assessment — 0.53 proportion of participants
Phase 4 N=30 Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis
Hand Dermatosis
Primary: Proportion of Subjects With at Least 1-grade Improvement From Baseline to Day 15 in Investigator's Static Global Assessment Score (ISGA) Score — 96.7 Percentage of…
Phase 3 N=133 A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)
Moderate to Severe Atopic Hand and Foot Dermatitis
Primary: Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 — 16.7; 40.3 Percentage of participants — p==0.0030
N/A N=27 Hands on - a Hand Care Guide in Systemic Sclerosis
Scleroderma
Primary: Cochin Hand Functional Scale — 19.24 units on a scale
Phase 4 N=24 Evaluating Treatment Resistant Dermatitis TaroIIR
Atopic Dermatitis · Psoriasis
Primary: Investigator Global Assessment- Atopic Dermatitis — 1.7; 1.5 units on a scale
Phase 2 N=12 Study of Apremilast in Atopic or Contact Dermatitis
Atopic Dermatitis · Allergic Contact Dermatitis
Primary: Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) by Two or More Points — 2 participants
N/A N=60 Treatment of Staphylococcus Aureus Colonization in Hand Eczema
Hand Eczema · Foot Eczema
Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035
N/A N=10 Dermatosis Papulosa Nigra
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
N/A N=28 Removal of Dermal Exposure to Phthalate Ester by Hand Washing
Environmental Exposure · Exposure to Pollution
Primary: Amount of Diethylhexyl Phthalate Removed From Hand — 94.64; 8.74 percentage of DEHP removed
Phase 2 N=97 Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema
Chronic Hand Dermatitis
Primary: Percent Change From Baseline in Modified Total Lesion Symptom Score (mTLSS) — -49.5; -71.3; -29.9 percentage change
Phase 4 N=11 Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis
Psoriasis
Primary: Efficacy as Measured by the Mean Percentage Change in the Product of Static Physician Global Assessment (sPGA) and Body Surface Area (BSA). — 53.06; 65.6 percentage of…
Phase 3 N=596 Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema
Eczema
Primary: Number of Participants Who Responded as Per Physician's Global Assessment (PGA) at Week 24 — 58; 14; 60; 30 Participants — p=<0.001
Phase 3 N=487 Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema
Chronic Hand Eczema
Primary: Number of Participants With IGA-CHE TS at Week 16 — 64; 16 Participants — p=0.006
N/A N=148,166 Trends in the Epidemiology and Treatment of Atopic Dermatitis in the United Kingdom (UK)
Atopic Dermatitis Eczema · Atopic Dermatitis · Eczema
Primary: Prescription Rates for Atopic Dermatitis Related Treatments: Emollients and Soap Substitutes — 76095 Participants
N/A N=8 308nm Excimer Laser for Treatment of Fingernail Psoriasis
Nail Psoriasis
Primary: Modified NAPSI Score (Nail Psoriasis Severity Index) — 6.3; 6.0 units on a scale
N/A N=1,260 A Community-based Assessment of Skin Care, Allergies, and Eczema
Atopic Dermatitis · Atopic Disorders · Eczema
Primary: Provider-diagnosed Atopic Dermatitis — 217.7; 268.5 Participants with imputed values — p=0.019
Phase 4 N=33 A Two-week Crossover Evaluation of Two Hand Antiseptic Products on Skin Condition in Healthy Human Subjects
Healthy
Primary: Change From Baseline in Skin Health, Visual Skin Score (VSS) at 14 Days — 0.1; 0.4 units on a scale
N/A N=9 Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
Atopic Dermatitis · Eczema
Primary: SCORAD Change Score — 33.34 Change Score
Phase 3 N=473 Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)
Chronic Hand Eczema
Primary: Number of Participants With IGA-CHE TS at Week 16 — 91; 11 Participants — p=<0.001
Phase 2 N=186 Topical Ruxolitinib Evaluation in Chronic Hand Eczema
Hand Eczema
Primary: Percentage of Participants With Investigator's Global Assessment-Chronic Hand Eczema Treatment Success (IGA-CHE-TS) at Week 16 — 53.2; 10.9 percentage of participants…
N/A N=32 Insulin Sensitivity in Patients With Atopic Dermatitis
Atopic Dermatitis/Eczema · Type 2 Diabetes
Primary: Insulin Sensitivity Difference Between Patients With Atopic Dermatitis and Controls — 9.8; 9.2 mg glucose/kg body mass/minute
Phase 2 N=200 A NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier
Dermatitis, Atopic
Primary: Skin Barrier Strengthening Effect by Measurement of Trans Epidermal Water Loss (TEWL) Before and After Induction of Skin Irritation — 19.790; 24.680; 29.648; 28.646 TEWL…
Phase 2 N=41 Secukinumab for Treatment of Atopic Dermatitis
Atopic Dermatitis
Primary: Fold-Change in Epidermal Thickness of Lesional Skin — 1.15; 1.5; 1.18; -1 fold-change
N/A N=13 Management of Palmar Hyperhidrosis With Hydrogel-based Iontophoresis
Hyperhidrosis · Hyperhidrosis Palmaris et Plantaris
Primary: Change From Baseline in Palmar Sweat Production — 44.8; 43.2; 37.8; 24.9 mg/min
N/A N=133 Skin Health and Effectiveness of Standardized Skin Care Regimens in Nursing Home Residents
Xerosis Cutis
Primary: Change From Baseline in Overall Dry Skin Score (ODS) — -0.9; -1.2; -0.9 units on a scale
Phase 4 N=22 Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Palmoplantar Psoriasis · Plaque Psoriasis
Primary: Palmoplantar Physician Global Assessment (ppPGA) — 3.47; 2.24 score on a scale
N/A N=328 Diagnostic Accuracy of "Three Rings Vulvoscopy" for Detection of Vulvar Dermatosis
Lichen Sclerosus · Lichen Planus · Lichen Simplex Chronicus
Primary: Diagnostic Accuracy of "Three Rings Vulvoscopy" by the "Vulvoscopy Index" for Detection of Vulvar Dermatosis — 72; 0; 10; 246 Participants — p=0.6108
N/A N=32 Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors
Skin Toxicities
Primary: Qualitative Data From Patients and Experts to Measure Anti-EGFR Therapy-specific Health-related Quality of Life (HRQL) — 2.70; 2.41; 2.70; 2.29 units on a scale